RZRunyu Zou

Runyu Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Runyu Zou has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Hanan El Marroun

    Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Center, Rotterdam, The Netherlands

    5 shared publications
  • Henning Tiemeier

    Department of Child and Adolescent Psychiatry, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Social and Behavioral Sciences, T.H. Chan School of Public Health, Harvard University, Boston, MA, United States

    5 shared publications
  • Tonya White

    National Institute of Mental Health, Bethesda, MD, USA

    5 shared publications
  • Manon Hillegers

    Department of Child and Adolescent Psychiatry, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands

    4 shared publications
  • Ryan L. Muetzel

    Department of Child and Adolescent Psychiatry, University Medical Center Rotterdam, Erasmus Medical Center, Rotterdam, the Netherlands

    4 shared publications
  • Hanan El Marroun

    Department of Child and Adolescent Psychiatry, Erasmus MC University Medical Center Rotterdam , Rotterdam, The Netherlands Department of Pediatrics, Erasmus MC University Medical Center Rotterdam , Rotterdam, The Netherlands Department of Psychology, Education and Child Studies, Erasmus School of Social and Behavioral Sciences, Erasmus University Rotterdam , Rotterdam, The Netherlands

    3 shared publications

Latest Publications

  • Open Access

    Investigating Exposure and Hazards of Micro- and Nanoplastics During Pregnancy and Early Life (AURORA Project): Protocol for an Interdisciplinary Study

    by Amanda M Durkin, Runyu Zou, Justin M Boucher, Matthew Sp Boyles, Jeske van Boxel, Mariona Bustamante, Emily A Christopher, Payam Dadvand, Hanna M Dusza, Majorie van Duursen, et al.

    Background: Micro- and nanoplastics (MNPs) are emerging pollutants of concern with ubiquitous presence in global ecosystems. MNPs pose potential implications for human health; however, the health impacts of MNP exposures are not yet understood. Recent evidence suggests that MNPs can cross the placental barrier, underlying the urgent need to understand their impact on reproductive health and development. Objective: The Actionable eUropean ROadmap for early-life health Risk Assessment of micro- and nanoplastics (AURORA) project will investigate MNP exposures and their biological and health effects during pregnancy and early life, which are critical periods due to heightened vulnerability to environmental stressors. The AURORA project will enhance exposure assessment capabilities for measuring MNPs, MNP-associated chemicals, and plastic additives in human tissues, including placenta and blood. Methods: In this interdisciplinary project, we will advance methods for in-depth characterization and scalable chemical analytical strategies, enabling high-resolution and large-scale toxicological, exposure assessment, and epidemiological studies. The AURORA project performs observational studies to investigate determinants and health impacts of MNPs by including 800 mother-child pairs from 2 existing birth cohorts and 110 women of reproductive age from a newly established cohort. This will be complemented by toxicological studies using a tiered-testing approach and epidemiological investigations to evaluate associations between maternal and prenatal MNP exposures and health perturbations, such as placental function, immune-inflammatory responses, oxidative stress, accelerated aging, endocrine disruption, and child growth and development. The ultimate goal of the AURORA project is to create an MNP risk assessment framework and identify the remaining knowledge gaps and priorities needed to comprehensively assess the impact of MNPs on early-life health. Results: In the first 3 years of this 5-year project (2021-2026), progress was made toward all objectives. This includes completion of recruitment and data collection for new and existing cohorts, development of analytical methodological protocols, and initiation of the toxicological tiered assessments. As of September 2024, data analysis is ongoing and results are expected to be published starting in 2025. Conclusions: As plastic pollution increases globally, it is imperative to understand the impact of MNPs on human health, particularly during vulnerable developmental stages such as early life. The contributions of the AURORA project will inform future risk assessment. International Registered Report Identifier (IRRID): DERR1-10.2196/63176


  • Open Access

    Investigating Exposure and Hazards of Micro- and Nanoplastics During Pregnancy and Early Life (AURORA Project): Protocol for an Interdisciplinary Study (Preprint)

    by Amanda M Durkin, Runyu Zou, Justin M Boucher, Matthew Sp Boyles, Jeske van Boxel, Mariona Bustamante, Emily A Christopher, Payam Dadvand, Hanna M Dusza, Majorie van Duursen, et al.

    BACKGROUND Micro- and nanoplastics (MNPs) are emerging pollutants of concern with ubiquitous presence in global ecosystems. MNPs pose potential implications for human health; however, the health impacts of MNP exposures are not yet understood. Recent evidence suggests that MNPs can cross the placental barrier, underlying the urgent need to understand their impact on reproductive health and development. OBJECTIVE The Actionable eUropean ROadmap for early-life health Risk Assessment of micro- and nanoplastics (AURORA) project will investigate MNP exposures and their biological and health effects during pregnancy and early life, which are critical periods due to heightened vulnerability to environmental stressors. The AURORA project will enhance exposure assessment capabilities for measuring MNPs, MNP-associated chemicals, and plastic additives in human tissues, including placenta and blood. METHODS In this interdisciplinary project, we will advance methods for in-depth characterization and scalable chemical analytical strategies, enabling high-resolution and large-scale toxicological, exposure assessment, and epidemiological studies. The AURORA project performs observational studies to investigate determinants and health impacts of MNPs by including 800 mother-child pairs from 2 existing birth cohorts and 110 women of reproductive age from a newly established cohort. This will be complemented by toxicological studies using a tiered-testing approach and epidemiological investigations to evaluate associations between maternal and prenatal MNP exposures and health perturbations, such as placental function, immune-inflammatory responses, oxidative stress, accelerated aging, endocrine disruption, and child growth and development. The ultimate goal of the AURORA project is to create an MNP risk assessment framework and identify the remaining knowledge gaps and priorities needed to comprehensively assess the impact of MNPs on early-life health. RESULTS In the first 3 years of this 5-year project (2021-2026), progress was made toward all objectives. This includes completion of recruitment and data collection for new and existing cohorts, development of analytical methodological protocols, and initiation of the toxicological tiered assessments. As of September 2024, data analysis is ongoing and results are expected to be published starting in 2025. CONCLUSIONS As plastic pollution increases globally, it is imperative to understand the impact of MNPs on human health, particularly during vulnerable developmental stages such as early life. The contributions of the AURORA project will inform future risk assessment. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/63176

  • Associations of Gestational Exposure to Air Pollution With Maternal Vitamin D Levels: A Meta-Analysis

    by Anne-Claire Binter, Akhgar Ghassabian, Runyu Zou, Hanan El Marroun, Aitana Lertxundi, Karen M Switkowski, Marisa Estarlich, Ana Cristina Rodríguez-Dehli, Ana Esplugues, Tanja Vrijkotte, et al.

    Objective Maternal vitamin D level is an important determinant of pregnancy and child health outcomes. Exposure to air pollution is suspected to increase the risk of vitamin D deficiency, but the evidence is scarce. We investigated the association between air pollution during pregnancy and maternal vitamin D levels. Methods A total of 15,935 pregnant women from 5 birth cohorts in Europe and U.S were included. Averaged concentrations of nitrogen oxides, fine and coarse particles, and composition of fine particles from conception until vitamin D measurement were estimated at participants’ residential addresses using land-use regression or other spatiotemporal models. Cohorts measured vitamin D as 25(OH)D or 25(OH)D3 levels in serum or plasma at early or mid-pregnancy. We defined suboptimal vitamin D levels as levels below 20 ng/mL. We performed logistic regression models for each cohort to estimate the association between air pollution exposure and suboptimal vitamin D levels and pooled cohort-specific estimates in a random-effect meta-analysis. Models were adjusted for sociodemographic and lifestyle characteristics and month of conception. Results We found an association between PM2.5 and higher odds of suboptimal vitamin D levels (i.e., below 20 ng/mL) (odds ratio per 5 μg/m3 increase in PM2.5, 1.43 95%CI: 1.02, 1.99). There was no association between other air pollutant exposure and vitamin D levels. Conclusions PM2.5 exposure might contribute to suboptimal levels of vitamin D in pregnancy. Reducing air pollution exposure should be a priority because vitamin D deficiency may adversely influence offspring development.


  • Maternal folate levels during pregnancy and offspring brain development in late childhood

    by Runyu Zou, Hanan El Marroun, Charlotte Cecil, Vincent W.V. Jaddoe, Manon Hillegers, Henning Tiemeier, Tonya White


  • Open Access

    Maternal polyunsaturated fatty acids during pregnancy and offspring brain development in childhood

    by Runyu Zou, Hanan El Marroun, Trudy Voortman, Manon Hillegers, Tonya White, Henning Tiemeier

    Emerging evidence suggests an association of maternal PUFA concentrations during pregnancy with child cognitive and neuropsychiatric outcomes such as intelligence and autistic traits. However, little is known about prenatal maternal PUFAs in relation to child brain development, which may underlie these associations. We aimed to investigate the association of maternal PUFA status during pregnancy with child brain morphology, including volumetric and white matter microstructure measures. This study was embedded in a prospective population-based study. In total, 1553 mother–child dyads of Dutch origin were included. Maternal plasma glycerophospholipid PUFAs were assessed in midpregnancy. Child brain morphologic outcomes, including total gray and white matter volumes, as well as white matter microstructure quantified by global fractional anisotropy and mean diffusivity, were measured using MRI (including diffusion tensor imaging) at age 9–11 y. Maternal ω-3 (n–3) long-chain PUFA (LC-PUFA) concentrations during pregnancy had an inverted U-shaped relation with child total gray volume (linear term: β: 16.7; 95% CI: 2.0, 31.5; quadratic term: β: –1.1; 95% CI: –2.1, –0.07) and total white matter volume (linear term: β: 15.7; 95% CI: 3.6, 27.8; quadratic term: β: –1.0; 95% CI: –1.8, –0.16). Maternal gestational ω-6 LC-PUFA concentrations did not predict brain volumetric differences in children, albeit the linolenic acid concentration was inversely associated with child total white matter volume. Maternal PUFA status during pregnancy was not related to child white matter microstructure. Sufficient maternal ω-3 PUFAs during pregnancy may be related to more optimal child brain development in the long term. In particular, exposure to lower ω-3 PUFA concentrations in fetal life was associated with less brain volume in childhood. Maternal ω-6 LC-PUFAs were not related to child brain morphology.


  • Open Access

    Association of Gestational Age at Birth With Brain Morphometry

    by Hanan El Marroun, Runyu Zou, Michelle F. Leeuwenburg, Eric A. P. Steegers, Irwin K. M. Reiss, Ryan L. Muetzel, Steven A. Kushner, Henning Tiemeier

    Gestational age at birth (GAB) is an important determinant of child health and development. Worldwide, approximately 13 million newborns are born preterm (GAB1 Prematurity is associated with morbidity and mortality,2,3 including neurodevelopmental problems, such as cerebral palsy, intellectual disability, learning disability, and poor motor development.4-6 Preterm birth is reportedly associated with increased risks of attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder,7-9 and psychiatric disorders in adulthood.10 In some countries, postterm birth (GAB≥42 weeks) accounts for up to 10% of births11 and is associated with adverse birth outcomes, increased neonatal mortality, cognitive impairment, and increased risk of ADHD.12


  • Open Access

    A prospective population-based study of gestational vitamin D status and brain morphology in preadolescents

    by Runyu Zou, Hanan El Marroun, John J. McGrath, Ryan L. Muetzel, Manon Hillegers, Tonya White, Henning Tiemeier


  • Exposure to Maternal Depressive Symptoms in Fetal Life or Childhood and Offspring Brain Development: A Population-Based Imaging Study

    by Runyu Zou, Henning Tiemeier, Jan van der Ende, Frank C. Verhulst, Ryan L. Muetzel, Tonya White, Manon Hillegers, Hanan El Marroun

    Objective:The authors examined associations of exposure to maternal depressive symptoms at different developmental stages from fetal life to preadolescence with child brain development, including v...


  • Prenatal exposure to maternal and paternal depressive symptoms and white matter microstructure in children

    by Hanan El Marroun, Runyu Zou, Ryan L. Muetzel, Vincent W. Jaddoe, Frank C. Verhulst, Tonya White, Henning Tiemeier

    Prenatal maternal depression has been associated with multiple problems in offspring involving affect, cognition, and neuroendocrine functioning. This suggests that prenatal depression influences neurodevelopment. However, the underlying neurodevelopmental mechanism remains unclear. We prospectively assessed whether maternal depressive symptoms during pregnancy and at the child's age 3 years are related to white matter microstructure in 690 children. The association of paternal depressive symptoms with childhood white matter microstructure was assessed to evaluate genetic or familial confounding. Parental depressive symptoms were measured using the Brief Symptom Inventory. In children aged 6–9 years, we used diffusion tensor imaging to assess white matter microstructure characteristics including fractional anisotropy (FA) and mean diffusivity (MD). Exposure to maternal depressive symptoms during pregnancy was associated with higher MD in the uncinate fasciculus and to lower FA and higher MD in the cingulum bundle. No associations of maternal depressive symptoms at the child's age of 3 years with white matter characteristics were observed. Paternal depressive symptoms also showed a trend toward significance for a lower FA in the cingulum bundle. Prenatal maternal depressive symptoms were associated with higher MD in the uncinate fasciculus and the cingulum bundle. These structures are part of the limbic system, which is involved in motivation, emotion, learning, and memory. As paternal depressive symptoms were also related to lower FA in the cingulum, the observed effect may partly reflect a genetic predisposition and shared environmental family factors and to a lesser extent a specific intrauterine effect.